- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00285454
Cell Repair in Heart Failure
A Phase I/II, Randomised, Double-blind, Placebo Controlled, Single-centre Study of Bone Marrow Mononuclear Cells by Percutaneous Retrograde Coronary Venous Delivery to Patients With Ischaemic Heart Failure and no Standard Revascularisation Options.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Objectives:
- Evaluate the safety of a single administration of bone marrow mononuclear cells by retrograde coronary venous delivery.
- Evaluate the bioactivity of bone marrow mononuclear cells in mediating increased perfusion in viable underperfused areas of myocardium.
- Evaluate the ability of bone marrow mononuclear cells to improve myocardial function specifically regional wall motion and cardiac synchronisation.
- Evaluate the use of potential bioactivity assays and clinical outcomes for assessing bone marrow mononuclear cell- induced myocardial changes.
Study Design:
A phase I/II, randomised, double-blind, placebo controlled, single-centre study of bone marrow mononuclear cells by percutaneous retrograde coronary venous delivery to patients with ischaemic heart failure and no standard revascularisation options.
Study Population:
Patients with symptomatic ischaemic heart failure, not amenable to conventional revascularisation strategies (PCI, CABG, LVAD) or transplantation.
Independent Eligibility:
The results of the screening procedures will be compiled and submitted to an independent interventional cardiologist and cardiac surgeon who are not associated with the study for consideration for enrolment. It will be the independent reviewer's responsibility to confirm eligibility prior to a patient participating in the study.
Product:
Autologous bone marrow mononuclear, the first 6 safety and feasibility patients (open-labelled) will receive a sub-population of Indium-111 labelled cells to assess feasibility of delivery. The remaining patients will either receive Active: Bone marrow mononuclear cells and 5 % HSA Placebo: 5% HSA
Route:
Retrograde coronary venous delivery The total dose of bone marrow mononuclear cells or placebo will be divided into two, each administered as a 10ml bolus into a selective coronary veins. There will be significant patient heterogeneity regarding size of ischaemic viable territory present and anatomy of venous system. We aim to treat two veins, individual SPECT and venogram results will be used to direct the venous anatomy to be targeted. An attempt will be made to cover as large an area as possible of a patient's ischaemic viable territory. The total dose of cells will remain constant between patients.
Safety:
The first 6 patients will receive cells as an adjunct to Cardiac resynchronization Therapy and ICD. An external Data Safety and Monitoring Board has also been appointed to oversee this study.
Study Type
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
Middlesex
-
London, Middlesex, United Kingdom, SW3 6LR
- The Department of Gene Therapy, The National Heart and Lung Institute, Imperial College London and The Royal Brompton Hospital.
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Symptomatic ischaemic multi-vessel coronary artery disease (CAD) not suitable for standard revascularization procedures such as CABG, PCI, LVAD, or heart transplant.
- Area of reversible inducible ischaemia (>10% of LV on SPECT) performed not more than six months prior to study treatment.
- LVEF < 45% on optimal medical therapy.
- NYHA class II- IV patient stable on optimal medical therapy for at least 30 days.
- Written informed consent and agree to attend hospital appointments for 1 year.
- Male and females 18 to 80 years of age.
Exclusion Criteria:
- Left ventricular aneurysm or thrombus.
- Thoracic aortic aneurysm.
- Congenital Heart disease
- Acute unstable angina, idiopathic cardiomyopathy, life-threatening ventricular arrhythmias, recent (less than 6 weeks).
- Contraindication to MRI or any other study procedure.
- Presence or history of cancer (except low grade and fully resolved non-melanoma skin malignancy).
- Any co-morbidity likely to reduce short- term survival or which may interfere with functional testing.
- Recent myocardial infarction < 6mths.
- Cerebral vascular accident < 6mths.
- Active hepatitis, receiving immunosuppressive therapy, undergoing haemodialysis.
- Clinically significant abnormal haematology.
- Recent history of alcoholism, drug abuse, or severe emotional, behavioural, or psychiatric problems.
- Fertile women who are pregnant, nursing, or using no form of contraception.
- Receiving experimental medications or participating in another study within 12 weeks of enrolment into this study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
Efficacy
|
Safety: up to one year
|
Co-primary endpoints at 180 Days
|
Perfusion (MIBI SPECT)
|
Function (CMR)
|
Secondary Outcome Measures
Outcome Measure |
---|
QOL
|
Efficacy: at 180 days
|
Perfusion (CMR)
|
Function (ECHO, SPECT)
|
Exercise (VO2 Max)
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Eric WF Alton, The Department of Gene Therapy, The NHLI Imperial College London
- Principal Investigator: Jonathan R Clague, The Royal Brompton Hospital London
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Amanda Heinl-Green
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Ischemia
-
University Hospital, Strasbourg, FranceTerminatedVascular Surgery | Ischemia-reperfusion | Ischemia PreconditioningFrance
-
Beytepe Murat Erdi Eker State HospitalCompletedAnterior Segment Ischemia (Diagnosis)
-
University Hospital, Strasbourg, FranceCompletedSkeletal Muscle Ischemia | Severe Lower Limb Ischemia | Mitochondrial DysfunctionFrance
-
Egyptian Cerebro-Cardio-Vascular AssociationUnknownRisk Factor, Cardiovascular | Ischemia, Myocardial | Ischemia, Cerebral
-
The First Affiliated Hospital with Nanjing Medical...RecruitingHepatic IschemiaChina
-
Maastricht University Medical CenterUnknownIschemia-ReperfusionNetherlands
-
Technische Universität DresdenRecruitingRetinal IschemiaGermany
-
Centre Hospitalier Universitaire de NiceCompleted
-
Attikon HospitalUniversity Hospital of PatrasCompleted
-
Beth Israel Deaconess Medical CenterWithdrawn
Clinical Trials on Retrograde coronary venous delivery of cells.
-
Universitätsmedizin MannheimUniversity Heart Center Freiburg - Bad KrozingenUnknownCoronary Artery Disease | Percutaneous Coronary Intervention | Chronic Total OcclusionGermany
-
Sidney Kimmel Comprehensive Cancer Center at Johns...WithdrawnPancreatic AdenocarcinomaUnited States
-
Duke UniversityDuke Clinical Research InstituteWithdrawnHeart Failure | Acute Myocardial Infarction
-
Medical University of ViennaCompletedMyocardial InfarctionAustria
-
University of MinnesotaCompleted
-
Centre hospitalier de l'Université de Montréal...Maisonneuve-Rosemont Hospital; Centre de Recherche du Centre Hospitalier de... and other collaboratorsCompletedMyocardial Infarct | Heart FailureCanada
-
Oxford University Hospitals NHS TrustNational Institute for Health Research, United KingdomTerminatedHeart Failure | Ischemic CardiomyopathyUnited Kingdom
-
Indiana UniversityRecruitingCoronary Artery Disease | Cisplatin Adverse Reaction | Lipid Disorder | Survivorship | Hypogonadism, Male | Testicular Cancer | Bone Marrow Transplant Complications | ASCVDUnited States
-
University Health Network, TorontoMiltenyi Biotec, Inc.CompletedHeart Failure | Coronary Artery Bypass Surgery | Heart AttackCanada
-
Universidad de AntioquiaInstituto Colombiano para el Desarrollo de la Ciencia y la Tecnología (COLCIENCIAS)Completed